Cargando…

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

MET dysregulation is an oncogenic driver in non–small-cell lung cancer (NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients with epidermal growth factor receptor (EGFR)–mutated disease. This study was conducted to determine safety and preliminary efficacy of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCoach, Caroline E., Yu, Aiming, Gandara, David R., Riess, Jonathan W., Vang, Daniel P., Li, Tiahong, Lara, Primo N., Gubens, Matthew, Lara, Frances, Mack, Philip C., Beckett, Laurel A., Kelly, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140807/ https://www.ncbi.nlm.nih.gov/pubmed/34036220 http://dx.doi.org/10.1200/PO.20.00279

Ejemplares similares

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
por: Gautschi, Oliver, et al.
Publicado: (2021)

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)
por: Riess, Jonathan W, et al.
Publicado: (2021)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
por: Velazquez, Ana I., et al.
Publicado: (2020)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Using Time-Varying Covariates in Multilevel Growth Models
por: McCoach, D. Betsy, et al.
Publicado: (2010)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
por: Kujtan, Lara, et al.
Publicado: (2023)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report
por: Choi, Wonyoung, et al.
Publicado: (2022)

Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
por: Kim, Tae Woo, et al.
Publicado: (2022)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
por: Qin, Shukui, et al.
Publicado: (2019)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan, Aaron C, et al.
Publicado: (2021)

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Publicado: (2020)

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
por: Lin, Chien-Yu, et al.
Publicado: (2022)

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
por: Reckamp, Karen L., et al.
Publicado: (2019)

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients
por: Lo, Ernest N., et al.
Publicado: (2015)

Testing for intersectional measurement invariance with the alignment method: Evaluation of the 8‐item patient health questionnaire
por: Cintron, Dakota W., et al.
Publicado: (2023)

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts
por: Zhu, Kaibin, et al.
Publicado: (2021)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
por: Wilgucki, Molly, et al.
Publicado: (2022)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
por: Chou, Yun-Tse, et al.
Publicado: (2022)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
por: Huang, Keqiang, et al.
Publicado: (2018)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
por: Zhao, Zhi-Mei, et al.
Publicado: (2021)

Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer
por: Sandoval, Leticia, et al.
Publicado: (2023)

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022)

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mu49qf4uruimmfp9lg8qluo5oc